These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

848 related articles for article (PubMed ID: 33755656)

  • 21. Drugs for atrial fibrillation.
    Med Lett Drugs Ther; 2019 Sep; 61(1580):137-144. PubMed ID: 31599871
    [No Abstract]   [Full Text] [Related]  

  • 22. Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments.
    Naegele M; Flammer AJ; Enseleit F; Ruschitzka F
    Swiss Med Wkly; 2016; 146():w14295. PubMed ID: 26968014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibitors.
    Kuhn M
    AACN Clin Issues Crit Care Nurs; 1992 May; 3(2):461-71. PubMed ID: 1576040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ivabradine for treatment of heart failure.
    Bocchi EA; Salemi VMC
    Expert Opin Drug Saf; 2019 May; 18(5):393-402. PubMed ID: 31074301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of angiotensin receptor blockers in the treatment of chronic heart failure.
    Irons BK; Tsikouris JP; Thomas AA
    J Cardiovasc Pharmacol; 2004 Dec; 44(6):718-24. PubMed ID: 15550793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study.
    Fröhlich H; Henning F; Täger T; Schellberg D; Grundtvig M; Goode K; Corletto A; Kazmi S; Hole T; Katus HA; Atar D; Cleland JGF; Agewall S; Frankenstein L; Clark AL
    Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):82-92. PubMed ID: 28475676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis.
    Li H; Duan Y; Chen B; Zhao Y; Su W; Wang S; Wu J; Lu L
    Medicine (Baltimore); 2020 Jan; 99(5):e18341. PubMed ID: 32000355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognosis of heart failure treated with digoxin or with ivabradine: A cohort study in the community.
    Guzman M; Gomez R; Romero SP; Aranda R; Andrey JL; Pedrosa MJ; Egido J; Gomez F
    Int J Clin Pract; 2018 Nov; 72(11):e13217. PubMed ID: 30248211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
    Aronow WS
    J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors?
    Francis GS; Gassler JP
    Cleve Clin J Med; 2001 Mar; 68(3):185-6. PubMed ID: 11263844
    [No Abstract]   [Full Text] [Related]  

  • 31. New drugs for the treatment of chronic heart failure with a reduced ejection fraction: What the future may hold.
    Sciatti E; Dallapellegrina L; Metra M; Lombardi CM
    J Cardiovasc Med (Hagerstown); 2019 Oct; 20(10):650-659. PubMed ID: 31397687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing the treatment of heart failure.
    Giles TD
    Curr Opin Cardiol; 1994 Jul; 9 Suppl 1():S21-7. PubMed ID: 7827370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
    Saito M; Nakayama D; Takada M; Hirooka K; Yasumura Y
    J Clin Pharm Ther; 2006 Dec; 31(6):535-40. PubMed ID: 17176359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
    Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
    Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction.
    Nyolczas N; Dékány M; Muk B; Szabó B
    Adv Exp Med Biol; 2018; 1067():31-45. PubMed ID: 29086392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ivabradine (Corlanor) for Heart Failure.
    Davis K; Dietrich E
    Am Fam Physician; 2016 Apr; 93(8):682-4. PubMed ID: 27175841
    [No Abstract]   [Full Text] [Related]  

  • 37. Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review.
    Hindi J; Fréchette-Le Bel M; Rouleau JL; de Denus S
    Ann Pharmacother; 2024 Mar; 58(3):255-272. PubMed ID: 37338205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Management Strategies in Heart Failure.
    Owens AT; Brozena SC; Jessup M
    Circ Res; 2016 Feb; 118(3):480-95. PubMed ID: 26846642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of heart failure management in the elderly population.
    Cheng JW; Nayar M
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):233-49. PubMed ID: 19948300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.
    Dorosch T; Ganzer CA; Lin M; Seifan A
    Curr Pain Headache Rep; 2019 Sep; 23(11):85. PubMed ID: 31515634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.